A detailed history of Rhumbline Advisers transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 6,302 shares of GLSI stock, worth $85,392. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,302
Previous 6,799 7.31%
Holding current value
$85,392
Previous $117,000 23.08%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$12.99 - $17.58 $6,456 - $8,737
-497 Reduced 7.31%
6,302 $90,000
Q2 2024

Aug 01, 2024

BUY
$12.07 - $19.04 $82,063 - $129,452
6,799 New
6,799 $117,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $174M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.